Science-Driven Efficacy
We offer in vivo pharmacology services to Pharmaceutical, Biotech and Agrofood companies to assess the efficacy and mechanisms of action of health products addressing Metabolic Diseases, GI Disorders and Muscle-Wasting Conditions.
We offer tailor-made preclinical in vivo efficacy studies.
With over 80 years of cumulative experience, knowledge and skills in the study of Metabolic diseases, GI disorders and Muscle-wasting conditions, we excel in the development of relevant disease models and the mastery of gold-standard methods that both ensure accurate, reliable and high-added value data.
"We have enjoyed working with the Biomeostasis team a number of times. They are highly committed to the projects - the quality of their work was high, and communication and flexibility have been great. The team is professional and customer-oriented."
"We have worked with Biomeostasis for a couple of our studies over the years, and the clear data generated has allowed us to make key decisions in our programs We have appreciated their guidance, expertise and team work in the study experimental design. Their dedication and flexibility has helped us achieve our program goals in a timely manner which we appreciate. We would look forward to working with them again in the future to support our metabolic studies."
"Simply stated, Biomeostasis was the best CRO for our rodent metabolic studies that we could identify. We have now performed several studies and remain highly satisfied. The scientists at Biomeostasis are very knowledgeable, reliable and efficient. Highly recommended!"
"We have recently employed Biomeostasis in a NAFLD/NASH study using their DIO model. The execution of the planned study was flawless. We are also very pleased with the level of commitment prior and after the study to help us set it up optimally, understand the complexity of the model and the results generated. In short, they have my full endorsement."
"Biomeostasis worked diligently in a professional manner during one of our preclinical rodent studies. The project, while challenging, was well conducted and reported in a professional manner. Julien and his team leaned in and worked to solve issue and make in stream adjustments to get us the best results."
Our expertise
Metabolic diseases
Metabolic diseases, such as obesity, diabetes, dyslipidemia, or NAFL/NASH, affect millions of people worldwide and can severely affect their quality of life. While treatments have improved for many of these diseases, a high need of developed, safe, and effective therapeutics remains. Thanks to our strong expertise in metabolic diseases and their complications as well as in the preclinical evaluation of your compound, BIOMEOSTASIS can help you in your development process.
Obesity
Excess body fat impacting health Learn more
MASLD/MASH
Metabolic Dysfunction-associated liver diseases Learn more
Atherosclerosis
Artery blockage leading to heart disease Learn more
Diabetes
Disruption of insulin action & glucose homeostasis Learn more
Binge eating
The most common eating disorder worldwide Learn more
GI disorders
GI disorders include conditions such as constipation, diarrhea, and inflammatory bowel diseases (Crohn’s disease, ulcerative colitis…). At BIOMEOSTASIS, based on our expertise in these therapeutic areas, we developed specific rodent models of such disorders that constitutes powerful tools for the preclinical assessment of your compounds.
CONSTIPATION
A chronic condition that negatively impacts quality of life Learn more
IBD
Inflammatory conditions of the GI track Learn more
Muscle-wasting
Muscle wasting is a debilitating condition that develops with ageing as a physiological response to fasting or malnutrition, and in many diseases, including cancer-associated cachexia, sarcopenia diabetes, or cardiac failure. The loss of muscle mass or strength primarily results from excessive protein breakdown and reduced protein synthesis. Genetic diseases such as in the Duchenne muscular Dystrophy can also lead to muscular dysfunction. The loss of muscle function can lead to reduced quality of life, increased morbidity and mortality.
SARCOPENIA
Age-related muscle loss Learn more
DMD
Genetic disorder causing muscle degeneration Learn more
CACHEXIA
Severe muscle wasting and weight loss conditionLearn more
We help you optimize and anticipate the success of your health products.
From screening to chronic treatment studies, our established rodent models and experimental paradigms allow you to obtain high-added value data on the efficacy and mechanisms of action of your health products in order to optimize and anticipate their clinical success.
“in vivo VERITAS !”
Founded in 2010 by Bruno BARIOHAY, Ph.D. and Julien ROUX, Ph.D., Biomeostasis has been implicated in more than three hundred and fifty in vivo preclinical projects to date. The company endeavors to put its corporate values, i.e., Quality, Ethics and Flexibility, at the heart of each project. While these values are now well recognized worldwide, the company is proud to display a near 100% customer satisfaction rate. This recognition is a result of our passion, our listening to customers and of an expert scientific team dedicated to each of the projects conducted at Biomeostasis.
